Usynova

News

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront.

News

A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.